Vaxart
Logotype for Vaxart Inc

Vaxart (VXRT) investor relations material

Vaxart Q3 2026 & Fireside Chat earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vaxart Inc
Q3 2026 & Fireside Chat earnings summary6 Nov, 2026

Executive summary

  • Phase 2b COVID-19 study includes a 400-participant sentinel cohort and ~5,000-participant main cohort; full-study efficacy and safety data are targeted for mid-2027.

  • Focus remains on completing analytical testing and clinical milestones while seeking funding and partnerships to extend runway.

Financial highlights

  • Q3 revenue was $10.6M vs. $72.4M in Q3 2025, down 85% as government-contract activity declined; revenue included $7.5M in government-contract and $2.9M in collaboration revenue.

  • Q3 R&D expense was $22.8M vs. $75.9M; G&A was $5.1M vs. $4.3M.

  • Q3 net loss was $17.7M, or $0.07/share, vs. $8.1M, or $0.04/share; operating loss was $17.3M vs. $7.8M.

  • Nine-month revenue was $77.0M vs. $133.0M; net loss was $26.0M vs. $38.7M.

  • Cash, cash equivalents and short-term investments totaled $65.5M at September 30, 2026.

Outlook and guidance

  • Full-study COVID-19 topline efficacy and safety results are expected by mid-2027, following participant follow-up, analytical testing, external lab processing and BARDA review.

  • Management aims to submit the Phase 2b package to the FDA after the readout; Dynavax may elect to assume further development for a $50M payment.

  • Cash resources are expected to fund operations into Q2 2027; additional capital may be needed, with further expense reductions or deferrals among planned responses if financing is unavailable on acceptable terms.

  • Norovirus development could advance to the next clinical stage in 2027, subject to partnership or other funding; additional indications depend on appropriate financial or strategic support.

  • Detailed sentinel-data timing remains uncertain; external lab completion and BARDA review and approval govern potential disclosure.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Vaxart earnings date

Logotype for Vaxart Inc
Q4 202618 Mar, 2027
Vaxart
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Vaxart earnings date

Logotype for Vaxart Inc
Q4 202618 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Vaxart Inc. is a biotechnology company focused on developing oral vaccines that are administered using tablet formulations rather than injections. The company's proprietary oral vaccine platform is designed to stimulate immune responses in mucosal tissues, which are the first line of defense against many infections. Vaxart's vaccine candidates target a range of infectious diseases, including influenza, norovirus, and COVID-19. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.